Chosa Oncology is advancing cancer treatment through its innovative technologies, primarily the iCIP™ platform, which integrates the LiPlaCis® formulation with a unique Drug Response Predictor (DRP®). The LiPlaCis® product utilizes liposomal technology to deliver cisplatin, a common chemotherapy drug, in a way that enhances its efficacy while minimizing toxicity. This formulation is designed to improve the therapeutic outcomes for patients with metastatic breast cancer by selecting individuals who are most likely to benefit from cisplatin treatment based on their tumor's genetic profile. The DRP® analyzes 205 relevant genes in a patient's tumor to predict their response to cisplatin, thereby guiding treatment decisions and potentially increasing survival rates.

The combination of LiPlaCis® and the DRP® represents a significant advancement in precision oncology, as it allows for tailored treatment strategies that can lead to better patient outcomes. Chosa Oncology's approach not only aims to enhance the effectiveness of cisplatin but also seeks to reduce the number of patients who undergo ineffective treatments. By identifying those who are unlikely to respond to cisplatin, the company can direct patients toward alternative therapies, thereby optimizing the overall treatment landscape in oncology. This innovative use of biomarker technology positions Chosa Oncology at the forefront of personalized cancer care, with the potential to significantly impact the market for cancer therapies, particularly in conjunction with immunotherapy options.

Denmark

CHOSA’s key product is a major upgrade of Cisplatin – a cornerstone drug in oncology It incorporates two precision oncology technologies to improve efficacy & reduce side-effects

Chosa Oncology

Company Details